BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34378076)

  • 1. Identification of predictors for brain metastasis in newly diagnosed non-small cell lung cancer: a single-center cohort study.
    Park S; Lee SM; Ahn Y; Kim M; Suh CH; Do KH; Seo JB
    Eur Radiol; 2022 Feb; 32(2):990-1001. PubMed ID: 34378076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Non-Small Cell Lung Cancer.
    Kim M; Suh CH; Lee SM; Kim HC; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
    Radiology; 2020 Nov; 297(2):419-427. PubMed ID: 32840470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
    Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
    Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
    Kim M; Suh CH; Lee SM; Park JE; Kim HC; Kim SO; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
    AJR Am J Roentgenol; 2021 Nov; 217(5):1184-1193. PubMed ID: 34037408
    [No Abstract]   [Full Text] [Related]  

  • 5. CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer: a systematic review and meta-analysis.
    Zhang H; Cai W; Wang Y; Liao M; Tian S
    Int J Clin Oncol; 2019 Jun; 24(6):649-659. PubMed ID: 30835006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
    Yang H; Wang K; Li S; Li Y; Yuan L
    Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
    [No Abstract]   [Full Text] [Related]  

  • 7. A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer.
    Li Y; Lv X; Chen C; Yu R; Wang B; Wang D; Hou D
    Eur Radiol Exp; 2024 Jan; 8(1):2. PubMed ID: 38169047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Air bronchogram on chest CT in radiological pure-solid appearance lung cancer: Correlation analysis with genetic pathological features and survival outcomes.
    Wang Z; Zhu W; Yang M; Du H; Zhou F; Song N; Wan Z; Zhu J; Li W
    Eur J Radiol; 2023 Dec; 169():111194. PubMed ID: 37976762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.
    Choi CM; Kim MY; Hwang HJ; Lee JB; Kim WS
    Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
    Guan J; Xiao NJ; Chen M; Zhou WL; Zhang YW; Wang S; Dai YM; Li L; Zhang Y; Li QY; Li XZ; Yang M; Wu HB; Chen LH; Liu LY
    Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.
    Liu Y; Kim J; Qu F; Liu S; Wang H; Balagurunathan Y; Ye Z; Gillies RJ
    Radiology; 2016 Jul; 280(1):271-80. PubMed ID: 26937803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early stage non-small cell lung cancer patients need brain imaging regardless of symptoms.
    Ando T; Kage H; Saito M; Amano Y; Goto Y; Nakajima J; Nagase T
    Int J Clin Oncol; 2018 Aug; 23(4):641-646. PubMed ID: 29484515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing EGFR gene mutation status in non-small cell lung cancer with imaging features from PET/CT.
    Jiang M; Zhang Y; Xu J; Ji M; Guo Y; Guo Y; Xiao J; Yao X; Shi H; Zeng M
    Nucl Med Commun; 2019 Aug; 40(8):842-849. PubMed ID: 31290849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
    Lee EY; Khong PL; Lee VH; Qian W; Yu X; Wong MP
    Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
    BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
    Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ
    J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
    Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M
    Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer.
    Mori M; Hayashi H; Fukuda M; Honda S; Kitazaki T; Shigematsu K; Matsuyama N; Otsubo M; Nagayasu T; Hashisako M; Tabata K; Uetani M; Ashizawa K
    Thorac Cancer; 2019 Apr; 10(4):872-879. PubMed ID: 30811109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
    Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
    Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.